Cell adhesion-mediated drug resistance (CAM-DR) by the bone marrow (BM) is fundamental to multiple myeloma (MM) propagation and survival. Targeting BM protection to increase the efficacy of current anti-myeloma treatment has not been extensively pursued. To extend the understanding of CAM-DR, we hypothesized that the cytotoxic effects of novel anti-myeloma agents may be abrogated by the presence of BM stroma cells (BMSCs) and restored by addition of the CXCL12 antagonist NOX-A12 or the CXCR4 inhibitor plerixafor. Following this hypothesis, we evaluated different anti-myeloma agents alone, with BMSCs and when combined with plerixafor or NOX-A12. We verified CXCR4, CD49d (also termed ITGA4) and CD44 as essential mediators of BM adhesion on MM cells. Additionally, we show that CXCR7, the second receptor of stromal-derived-factor-1 (CXCL12), is highly expressed in active MM. Co-culture proved that cotreatment with plerixafor or NOX-A12, the latter inhibiting CXCR4 and CXCR7, functionally interfered with MM chemotaxis to the BM. This led to the resensitization of MM cells to the anti-myeloma agents vorinostat and pomalidomide and both proteasome inhibitors bortezomib and carfilzomib. Within a multicentre phase I/II study, NOX-A12 was tested in combination with bortezomib-dexamethasone, underlining the feasibility of NOX-A12 as an active add-on agent to antagonize myeloma CAM-DR.
Multiple myeloma (MM) results from the proliferation of monoclonal plasma cells (PCs; Palumbo & Anderson, 2011) and typically presents with widespread involvement of the bone marrow (BM), including characteristic circulation of MM cells passaging out into the peripheral blood (PB) and re-entering the BM via an ongoing process termed homing (Van de Broek et al, 2008) . Important progress in MM has been made over the past decade with novel therapeutics, including proteasome inhibitors (PI), next-generation immunomodulatory drugs (IMiDs) and antibodies (abs) (Gay et al, 2013; McCarthy, 2013; Engelhardt et al, 2014; van de Donk et al, 2016) . However, these drugs may lose their efficacy in relapsed, refractory MM (RRMM) due to so-called cell adhesion-mediated drug resistance (CAM-DR; CXCR4 is a chemokine receptor with potent chemotactic activity (Heckmann et al, 2013) . In the physiological setting, it acts as a crucial mediator of homing and trafficking of healthy lymphocytes and haematopoietic stem cells, whereas in MM, it may also act as an inductor of the BM crosstalk, which leads to disease progression and dissemination (Stessman et al, 2013) . CXCR4 is activated upon binding of CXCL12 (also termed stromal cell-derived factor 1, SDF-1), its ligand, which induces homing of normal haematopoietic progenitors to the BM and attracts MM cells to their protective niche. The binding of CXCL12 to CXCR4 directly promotes PC survival and facilitates CAM-DR (Alsayed et al, 2007; Roccaro et al, 2014 Roccaro et al, , 2015 . Dissecting CXCL12-dependent cell trafficking and targeting the CXCL12/CXCR4-axis represents a promising therapeutic approach, particularly in RRMM with advanced BM microenvironment (BMM) involvement (Stessman et al, 2013) . Current BMM-targeting agents, such as the stem cell mobilizing CXCR4 antagonist plerixafor, a small molecule bicyclam derivative which binds to CXCR4, or the anti-CXCL12 L -ribonucleotide NOX-A12 (olaptesed pegol), are being assessed in in vitro and in vivo analyses, including phase I/II clinical trials (Hoellenriegel et al, 2014; Ludwig et al, 2014 Ludwig et al, , 2017 Roccaro et al, 2015; Greil et al, 2017) .
Based on our initial flow cytometry analyses, which detected significantly increased expression of CXCR4, CD49d and CD44 on the surface of malignant PCs taken from BM samples of patients with active MM, we further characterized CXCL12 and its second receptor CXCR7. To extend the understanding of their role for CAM-DR in MM, we hypothesized that the cytotoxic effects of novel agents may be abrogated by the presence of BM stroma cells (BMSCs), but may be inversely restored by addition of the CXCL12 antagonist, NOX-A12, or the CXCR4 inhibitor, plerixafor (Azab et al, 2009) . Following this hypothesis, we evaluated different anti-myeloma agents with regard to their effects on MM PC adhesion and tested their additive efficacy, if combined with plerixafor or NOX-A12. To bridge our in vitro results to clinical approaches, NOX-A12 was tested within a multicentre phase I/II study in combination with bortezomib-dexamethasone (VD), elucidating the value of a CXCL12 inhibitor in VD-pretreated RRMM patients (Ludwig et al, 2017) .
Methods

Cells and anti-myeloma agents
U266, RPMI-8226, L363, MOLT-4, NCI-H929 and the stromal cell line M2-10B4 were utilized (Oncotest, Freiburg, Germany) . MM cell line (MMCL) selection reflected the heterogeneity of MM with respect to different drug sensitivity and growth characteristics (Zlei et al, 2007; Udi et al, 2013) : U266 is a semi-adherent MMCL, RPMI-8226 shows adherent growth in up to 50% of cultured cells, L363 is derived from plasma cell leukaemia (PCL) and NCI-H929 is an IMiD-sensitive MMCL. (Fig S1) , which was chosen for subsequent in vitro experiments. M2-10B4 cells were used for co-culture studies based on prior studies (Engelhardt et al, 2000; Zlei et al, 2007; Sch€ uler et al, 2013; Udi et al, 2013) , which confirmed their favourable reproducibility and homogeneity compared to primary BMSCs or human BM cell lines. The BM layer was generated by plating 1910 6 M2-10B4 cells in a 24-well plate and discarding nonadherent cells after 2-3 days. MM cells were added to the monolayer and were simultaneously treated with anti-MM agents and 50 lg plerixafor, for 24 and 72 h, respectively. Bortezomib (1, 10, 20, 50, 100 nmol/l) was obtained from Janssen-Cilag, Neuss, Germany, NOX-A12 (100 nmol/l) from NOXXON (Berlin, Germany), carfilzomib (20, 50, 100 nmol/l) from BPBio (Aurora, CO, USA), pomalidomide (0Á1, 1, 10, 100 lmol/l) from Celgene (Summit, NJ, USA) and vorinostat (1, 3, 10, 30 lmol/l) and plerixafor (10, 50, 100 lmol/l) from Sigma-Aldrich (M€ unchen, Germany). All cells were cultured as described (Zlei et al, 2007; Udi et al, 2013) . CXCL12 stimulation was performed with human recombinant CXCL12 (30 nmol/l, PeproTech, Rocky Hill, NJ, USA). For combination studies, cells were pre-incubated for 30 min with plerixafor or NOX-A12. Drug doses were used based on previous studies and were in line with clinically relevant doses (Papandreou et al, 2004; Azab et al, 2009; Smith & Houghton, 2013; Liu et al, 2009, see below) . To differentiate MM cells and stromal cells, we used a PC gate that excluded large granular stromal cells, based on their forward (FSC) and side scatter characteristics (SSC) as done in comparable experiments for CLL co-cultures (Kurtova et al, 2009 ).
Detection of in vitro apoptosis
Viability was quantified by propidium iodide (SigmaAldrich) and annexinV-FITC (Calbiochem, Merck Millipore, Billerica, MA, USA) using flow cytometry (FACS Calibur System, BD Biosciences, Franklin Lakes, NJ, USA) before and after 1, 24 and 72 h.
Analysis of CXCR4 and CXCR7
For flow cytometry, cells were incubated with monoclonal abs for 10 min at 4°C (Table SI) . For CXCR4, both conformation-dependent abs (12G5 and 44717; R&D Systems, Minneapolis, MN, USA) and conformation-independent-abs (4G10; Santa Cruz Technology, Santa Cruz, CA, USA) were used, and CXCR7 was measured with the specific anti-CXCR7-PE-ab 11G8 (R&D; Zoughlami et al, 2012) , as specific staining of CXCR7 had previously been shown to be challenging (Berahovich et al, 2010) . Expression levels were 
Image cytometry, actin polymerization and Western blot
To pursue CXCR4 receptor internalization upon CXCL12 stimulation, we established an image cytometry protocol: surface and intracellular CXCR4 changes were assessed in U266, L363 and MOLT-4 cells. MOLT-4 cells were investigated using an initial staining protocol with the anti-CXCR4-AlexaFluor488-ab (44717; R&D Systems). The effect of CXCL12 stimulation and CXCR4 inhibition by plerixafor were also analysed: 1 9 10 6 cells were stained in duplicates with Live/Dead Far Red (Invitrogen, Carlsbad, CA, USA) to exclude dead cells, then treated with blocking solution (0.1% bovine serum albumin; Carl Roth, Karlsruhe, Germany/Life Technologies, Carlsbad, CA, USA) and surface CXCR4 was stained using the anti-CXCR4-PE-ab 4G10. Cells were fixed in 100 ll paraformaldehyde (4%) and permeabilized with a permeabilization buffer (0.1% saponin; Honeywell, Morristown, NJ, USA). Cells were resuspended in permeabilization buffer and stained with the 4G10-FITC-ab to label intracellular CXCR4. The samples were transferred into 8-well l-slides (Ibidi, Martinsried, Germany). Before image cytometry, 3 ll of 1 mg/ml DAPI solution (4 0 , 6-diamidin-2-phenylindol; Sigma-Aldrich) was added to stain the cell nuclei. Images were acquired with a ScanR high content screening station based on an Olympus IX-81 microscope using a 209 N.A. 0Á75 UPLSAPO objective and analysed using the ScanR analysis software (Olympus, Tokyo, Japan). To assess actin polymerization, U266 or L363 cells (1Á5 9 10 6 /ml) were suspended in RPMI 1640 medium with 0Á5% bovine serum albumin at 37°C and stimulated with 30 nmol/l CXCL12. After 15, 60, 120 and 300 s of stimulation, 400 ll of cell suspension were added to 100 ll of a solution containing 50 lg/ml FITC-labelled phalloidin, 50 mg/ml alysophosphatidylcholine and 37% formaldehyde in phosphate-buffered saline. Intracellular F-actin was measured by flow cytometry. Western blots were performed as described (Udi et al, 2013) . 
Patient characteristics
BM samples of MM patients (n = 59) were analysed using flow cytometry and compared to samples from patients with monoclonal gammopathy of undetermined significance (MGUS, n = 10) and healthy volunteers (n = 20). Patient characteristics are summarized in Table I . Among MM, MGUS and healthy volunteers, we compared MM-specific immunophenotype markers; in BM samples with low (≤5%), intermediate (>5% to <50%) and high (≥50%) PC infiltration, and in newly diagnosed (n = 16) or symptomatic patients (n = 23) versus those with long-term disease control (n = 20) as previously defined (Pessoa de Magalhães et al, 2013) . Additionally, we assessed CXCR7 expression. In a phase I/II study, NOX-A12 was tested in combination with VD (NOX-VD) and was given i.v. 1 h before bortezomib treatment (Ludwig et al, 2017) . The analyses were carried out according to the Declaration of Helsinki and good clinical practice. All patients gave their written informed consent for institutional-initiated research analyses of clinical outcome, conforming to our institutional review board guidelines.
Statistical analysis
Analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA) and GraphPad Prism 5 (GraphPad Prism Inc., San Diego, CA, USA) software. Spearman correlation coefficients between the expression of surface CD markers and continuously increasing BM infiltration rates were calculated. For the analysis of BM surface markers, Wilcoxon-two-sample tests and Kruskal-Wallis tests were applied, comparing MM, MGUS and healthy volunteers, and MM patients with lower versus higher BM infiltration. For the comparison of two conditions, the two-tailed t-test was applied. For testing of three groups, the ANOVA-one-way-test coupled with the Tukey-post-test was utilized. To test additive effects with agent combinations, the ANOVA-two-way-test coupled to the Bonferroni-post-test was chosen. The statistical tests were conducted as paired where appropriate. A P-value of <0Á05 was considered to be statistically significant and marked P < 0Á05*, P < 0Á01** and P < 0Á001***. Graphical representations of the data are given as means with error bars (standard error of the mean) or boxplots. 
Results
CXCR4 and other adhesion markers are increased in active MM
To test our hypothesis that the expression of adhesion markers on MM PCs may aid in designing novel treatment options, we first investigated the expression levels of CXCR4, CD49d and CD44 in BM samples of MM patients compared to MGUS and healthy volunteers. The detected increase in levels of CXCR4, CD49d and CD44 on CD138 + PCs reached significance for MM patients compared to healthy volunteers ( Fig 1A) . 
Plerixafor blocks CXCR4 detection and reduces CD49d and CD44 expression
To analyse the pattern of adhesion markers, we assessed CXCR4, CD49d and CD44 expression in U266, RPMI-8226 and L363 cells ( Fig S1A) . We also examined the alteration in adhesion markers, when cells were treated with bortezomib and plerixafor. Bortezomib (5 + 10 nmol/l) did not induce CXCR4 surface changes nor did it alter CD49d or CD44 expression after 24 and 72 h of therapy (Fig S1B a-c) . When using the conformation-dependent ab-clone 12G5, plerixafor resulted in significantly reduced surface CXCR4 detection (Fricker et al, 2006) . Concomitantly, a minor decrease in CD49d and CD44 expression after 72 h of plerixafor treatment was detected (Fig S1B b+c) . To demonstrate that these effects were not related to the intrinsic cytotoxicity of plerixafor, we also tested plerixafor alone, which did not induce relevant cytotoxicity in U266 or L363 ( Fig S2A+B) .
To determine, whether the observed effect of plerixafor on CXCR4 was due to an induced change in CXCR4 expression or due to differences in detection, we compared conformation-dependent CXCR4-abs (12G5, 44717) and the conformation-independent 4G10-ab (Zoughlami et al, 2012; Burger & Gribben, 2014) . Both 12G5 and 44717 allowed the detection of significantly less surface-CXCR4 after plerixafor (42-and 36-fold decrease, respectively), whereas with the conformation-independent clone 4G10 (FITC-or PE-coupled) CXCR4 remained unaltered (Fig S1C) . In agreement with previous data (Alsayed et al, 2007; Azab et al, 2009; Roccaro et al, 2015) , our results confirmed that plerixafor blocks the binding of the ab-clone 12G5, although a substantial difference in ab-specific CXCR4 detection with use of different abclones was notable. This indicated that plerixafor induces conformational changes, epitope blockage in CXCR4 or receptor internalization, which was subsequently tested via image cytometry (Fig 2) .
CXCL12 leads to CXCR4 internalization, which is inhibited by plerixafor
To visualize the pattern of CXCR4 expression and to pursue receptor internalization upon CXCL12 stimulation, we developed an image cytometry protocol. MOLT-4 cells were used as a control due to their high CXCR4 expression. With plerixafor and the ab 44717 both surface and intracellular CXCR4 detection were reduced (Fig 2A+B) , confirming prior flow cytometry measurements. In order to validate the specificity of our image cytometry protocol, we next compared CXCR4 expression of U266 and L363 cells: flow cytometry detected higher surface CXCR4 in U266 than L363 (Fig S1A) , which was in line with image cytometry (Fig 2C) . Moreover, we assessed CXCR4 in untreated, plerixafor-, plerixafor-and CXCL12-treated cells: CXCL12 stimulation led to a decrease in surface CXCR4 and increase in intracellular CXCR4. Using the conformation-independent 4G10-ab, plerixafor did not significantly change CXCR4: mean surface CXCR4 and intracellular CXCR4 expression without and with plerixafor was 60Á2% vs. 61Á6% (P = 0Á65) and 52Á1% vs. 38Á8% (P = 0Á23), respectively. Accordingly, surface and intracellular CXCR4 did not substantially change with CXCL12 plus plerixafor (Fig 2D) . Thus, in agreement with previous data (Alsayed et al, 2007; Azab et al, 2009 ) and as visualized via image cytometry, plerixaforinduced CXCR4 blockage was not accompanied by receptor internalization, different from what is observed upon CXCL12 stimulation alone (Fig 2D) .
Plerixafor restores sensitivity to bortezomib and pomalidomide in stromal cell co-culture
To examine both novel agents and stroma inhibitors, we next investigated the histone deacetylase inhibitor vorinostat, which was part of an Investigator Initiated Trial (IIT) in RRMM patients at our centre (Waldschmidt et al, 2015) , the third generation IMiD pomalidomide and both proteasome inhibitors bortezomib and carfilzomib. All four agents were tested as monotherapy, with stroma support (Fig 3A-D, left columns) , and in stromal cell co-culture with the respective agents plus plerixafor (Fig 3B+C, right columns) : dose-dependent cytotoxicity was confirmed for vorinostat, pomalidomide, bortezomib and carfilzomib after 24 and 72 h, whereas cytotoxic effects significantly decreased in the presence of stroma (P < 0Á001, Fig 3A-D , left column; Azab et al, 2009; Udi et al, 2013) . To explore whether the inhibition of adhesion could restore the cytotoxicity of each anti-myeloma agent, stromaculture with the respective agents plus plerixafor was assessed. This pre-treatment partially restored cytotoxicity, reaching significance for 100 lmol/l of pomalidomide and 20 and 50 nmol/l of bortezomib after 72 h as compared to co-culture conditions without plerixafor (Fig 3B+C, right column) . Increased cytotoxicity for vorinostat and carfilzomib when combined with plerixafor was also observed, but failed to reach statistical significance (Fig 3A+D, right column) . Of note, the stroma protection differed for various anti-myeloma agents, i.e., it was less protective for increasing vorinostat doses, more substantial for increasing exposure to bortezomib and pomalidomide and most for increasing doses of carfilzomib (Fig 3A-D) , although no significantly restored increase in cytotoxicity of carfilzomib could be observed with addition of plerixafor. These effects were not related to intrinsic cytotoxicity of plerixafor and NOX-A12 (Fig S2A+B) .
Plerixafor abrogates CXCL12-mediated ERK (MAPK1) and CXCR4 phosphorylation and actin polymerization
To explore the functional mechanisms responsible for the use of plerixafor to anti-MM-agents, we determined how CXCL12 stimulation and plerixafor treatment mechanistically mediate their effects: CXCL12 stimulation (5, 10 min) led to a significant decrease of surface CXCR4 (Fig 4A) , confirming image cytometry (Fig 2) . To verify the molecular targets of CXCL12, we performed Western blot analyses and detected an increase of ERK phosphorylation (pERK) (Alsayed et al, 2007) and stronger increase of CXCR4 phosphorylation (pCXCR4) at serine 339 (S339) after stimulation with CXCL12. Plerixafor pretreatment for 72 h led to the inhibition of both CXCL12-mediated activating steps, with stable pERK and pCXCR4 levels irresponsive to CXCL12 stimulation (Fig 4B) . When evaluating actin polymerization as a parameter of cell migration, we observed that CXCL12-induced actin polymerization in U266 and L363 cells could be abrogated by pre-treatment with plerixafor ( Fig 4C) . Plerixafor alone led to an initial increase in baseline pCXCR4 and actin polymerization (Azab et al, 2009; Udi et al, 2013) , confirming its partially agonistic function (Zhang et al, 2002; Kim et al, 2010) .
MMCLs and primary BM samples express CXCR7
CXCL12 displays a promising target in CAM-DR, because it is not only binding to CXCR4 but also to CXCR7, its second receptor which acts as a critical regulator protein for CXCL12 scavenging in splenic B-cells and as a co-activator of transendothelial migration (Mazzinghi et al, 2008; Wang et al, 2012) . CXCR7 expression has been described on activated endothelial, but not on MM cells (Azab et al, 2014) . We assessed CXCR7 on MMCLs and primary MM patients' (C+D) U266 and L363 cells were stained for surface CXCR4 (4G10-PE: red), intracellular CXCR4 (4G10-FITC: green), nuclei (DAPI: blue) and dead cells (Live/Dead assay: not shown). U266 and L363 cells (n = 5) were compared regarding their surface versus intracellular CXCR4 expression (C). Untreated U266 cells (n = 6), U266 cells stimulated with CXCL12 (30 nmol/l, 5 min, n = 6), U266 cells pre-treated with plerixafor (50 lmol/l, n = 4) and U266 cells pre-treated with both plerixafor (50 lmol/l) and stimulated with CXCL12 (30 nmol/l, 5 min, n = 4), were compared regarding their surface and intracellular CXCR4 expression (D).
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BM samples and observed substantial CXCR7 expression on U266, L363, NCI-H929 and primary MM samples (Fig 5A) . On patient BM samples, the majority of CD138 positive cells were positive for CXCR7 and CXCR4 (Fig 5B) . The percentage of CD138 positive cells was lower (median 15%) than the histologically determined level of BM infiltration (>50%), confirming CD138 to be a crude marker for MM (Frigyesi et al, 2014) . When comparing the expression of CXCR7 and CXCR4, we found that with a quarter of all cells expressing CXCR7 its expression was even higher than that of CXCR4. In a representative MM patient, initially with indolent disease and later progression, we also assessed serial BM   Fig 3. Co-culture induced resistance to vorinostat, pomalidomide, bortezomib and carfilzomib may be restored by plerixafor cotreatment, this effect was significant for bortezomib and pomalidomide. As histone deacetylase (HDAC) inhibitors show action in MM, which lead to drug approval (of e.g. panobinostat), and prior analyses assessed the antimyeloma action of bortezomib plus HDAC inhibitors (vorinostat), we tested the HDAC inhibitor vorinostat, the third-generation immunomodulatory drug pomalidomide and the two proteasome inhibitors (PI) bortezomib (reference PI) versus carfilzomib. These antimyeloma agents were chosen because all four drugs show notable differences: cytotoxic effects of vorinostat (A), pomalidomide (B), bortezomib (C) and carfilzomib (D) on MMCLs (U266, NCI-H929) in mono-culture versus co-culture and with versus without plerixafor are shown in A-D. Left column -Coculture experiments were performed using M2-10B4 stroma. U266 cells were used for vorinostat (1, 3, 10, 30 lmol/l; n = 4), bortezomib (10, 20 nmol/l n = 3) and carfilzomib (20, 50, 100 nmol/l, n = 3/5) and NCI-H929 cells were utilized for pomalidomide analyses (0Á1, 1, 10, 100; n = 3). Cytotoxicity was quantified by propidium iodide staining and flow cytometry. Right column -All cells were co-cultured with M2-10B4. Propidium iodide positive cells were measured after treatment with vorinostat, pomalidomide, bortezomib and carfilzomib after 72 h of treatment with or without plerixafor (50 lmol/l), which was added 1 h before the anti-myeloma agent. Our results demonstrated that in vitro carfilzomib and vorinostat and plerixafor may not be a particularly promising combination -as opposed to bortezomib and pomalidomide.
specimens: CXCR7 markedly increased with disease progression, which was more substantial than increases in CXCR4 and CD138 (Table SIII) .
NOX-A12 is an active add-on agent
Based on our results of CXCR7 expression on malignant PCs, we hypothesized that NOX-A12 as a CXCL12 inhibitor might act by a dual mechanism of both CXCR4-and CXCR7-mediated CAM-DR. We included data from two RRMM patients participating in the NOX-VD trial (Ludwig et al, 2017) in our in vitro analyses, which suggested that plerixafor and NOX-A12 may enhance anti-myeloma agents' potency. Our two patients were a thoroughly assessed subset out of a total of 28 patients included in this single arm phase I/II study: NOX-A12 was administered intravenously at increasing doses from 1, 2 and 4 mg/kg in cycles 1-8, with a standard bortezomib-dexamethasone schedule (Fig S3) . Our patients had light-chain (LC)-only MM, advanced disease with extensive osteolyses and BM infiltration (Table SIV) . NOX-VD induced impressive paraprotein reduction and was well-tolerated: Patient 1 showed a 15-fold serum free LC (SFLC)-reduction with 6Á6% LCs remaining after cycle 1. Despite this response, thrombocytopenia remained with BM PC persistence, which led to the decision to take her off the trial. In spite of her refractory MM, she lived on for 17 more months, surviving 13 years with her disease. Of interest, she had high-risk cytogenetics with del17p at NOX-trial inclusion. Similarly, Patient 2 displayed unfavourable cytogenetics with hypodiploidy, but also responded with 4Á6% of her k-LC-levels remaining after completion of eight NOX-VD cycles. In concordance, her anaemia improved (from 8.7g/dl to 12.6 g/dl), the BM infiltration decreased (from 90% to 30%) and bone pain completely subsided (Fig S3) . Progression-free survival without maintenance -which was not part of this study -was 13Á3 months. This patient remains alive and well, with an ongoing survival of 80 months (Table SIV) .
Carfilzomib efficacy when combined with NOX-A12
Our focus was to assess potential differences of bortezomib versus carfilzomib and plerixafor versus NOX-A12. We were also interested in elucidating the most efficacious carfilzomib treatment in different MMCLs (U266, L363), with shortterm carfilzomib use for 1 h vs. 3 days, with and without protective stromal cell co-culture. Moreover, our results of increased effects of bortezomib plus plerixafor versus lesser efficacy of carfilzomib plus plerixafor (Fig 3D) raised the question of whether NOX-A12, as a dual inhibitor of CXCR4-and CXCR7-mediated CAM-DR, was a more potent co-agent for carfilzomib. To test this hypothesis, MMCLs were treated in various conditions: in monoculture with an 1-h carfilzomib pulse to imitate the rapid in vivo pharmacokinetics and continuously in mono-and co-culture (Parlati et al, 2009; Herndon et al, 2013; Hurchla et al, 2013) . Carfilzomib proved to be cytotoxic in all treatment conditions, with strongest cytotoxicity in the continuous 3-day treatment. M2-10B4 support reduced carfilzomib's cytotoxicity (Fig 6A a+b) . Similarly to plerixafor, NOX-A12 co-treatment did not significantly enhance the cytotoxic effects of carfilzomib (Fig 6B) , with intrinsic NOX-A12 cytotoxicity being excluded in U266 and L363 mono-and co-culture experiments (Fig S2C-D) . We therefore hypothesized that the reduced additive effect seen for the combination of carfilzomib with plerixafor and NOX-A12 was related to intrinsic effects of carfilzomib on CXCR4-mediated CAM-DR. Fluorescence-activated cell sorting analysis indeed determined decreases of CD138 and CXCR4 surface expression in a dose-dependent manner after 1 h carfilzomib treatment of U266 cells (Fig 6C) . In L363 cells, CXCR4 in mono-and coculture remained stable upon carfilzomib treatment, while surface CD138 was again downregulated (Fig S4) . Of note, CD138 reduction has been observed after treatment with various anti-myeloma agents (Zlei et al, 2007; Gay et al, 2013; Sch€ uler et al, 2013; Udi et al, 2013; Touzeau et al, 2017) , and is therefore not unique to carfilzomib (Figs 6C + S4B). Given that L363 derived from PCL-cells are less BMM-dependent, we subsequently used U266 cells to elucidate the effect of carfilzomib on CXCR4 and its downstream pathway: treatment with carfilzomib for 1 h significantly reduced CXCR4 phosphorylation at S339, both without ( Fig 6D) and with CXCL12-stimulation (Fig 6F) , but did not reduce total CXCR4 (Fig 6D) , ERK or pERK (Fig 6E) , thereby excluding a general inhibition of phosphorylation or protein synthesis by carfilzomib.
Discussion
In this study, we assessed the role of the BM interaction on the propagation and drug sensitivity of MM cells. CXCR4, CD49d and CD44 were found to be increased in MM compared to MGUS and healthy volunteers, confirming all three as accessible therapeutic targets in MM. These findings are in agreement with prior reports showing that CXCL12 and its receptor CXCR4 are critical in the crosstalk of MM cells, to , NCI-H929) and in primary MM BM samples by flow cytometry (CXCR7 in MMCLs n = 4, in primary MM cells n = 9; CXCR4 (clone 4G10) in U266 n = 13, in L363 n = 15, in NCI-H929 n = 4, in primary MM cells n = 7). The results are shown as isotype-based mean expression of live cells. We chose the CXCR7 antibody (11G8), which was described as very specific in contrast to the polyclonal antibody 72100, the latter being defined as unspecific and less reliable (Berahovich et al, 2010) . (B) The expression of the adhesion molecules CD138, CXCR7 and CXCR4 was analysed in primary BM MM samples using flow cytometry (CD138 n = 9, CXCR7 n = 9, CXCR4 n = 7). All results are presented as box plots, with the whiskers marking minimal and maximal values.
overcome CAM-DR (Alsayed et al, 2007; Azab et al, 2009; Noborio-Hatano et al, 2009; Roccaro et al, 2014 Roccaro et al, , 2015 and that targeting the CXCL12/CXCR4-axis may widen treatment options in MM. We extended prior in vitro studies examining the combination of the CXCR4 inhibitor plerixafor with the novel anti-myeloma agents vorinostat, pomalidomide and both of the proteasome inhibitor, bortezomib and carfilzomib. Initial bortezomib experiments served as a reference and to specifically determine potential differences to vorinostat, pomalidomide and carfilzomib and to combinations of bortezomib plus plerixafor and carfilzomib plus NOX-A12. The cytotoxic effects of all four agents were substantially reduced in stromal cell co-culture, impressively demonstrating the myeloma-protection for all of them mediated by BMSCs. Addition of plerixafor to pomalidomide and bortezomib could restore their sensitivity to various extents, albeit significantly less with carfilzomib as compared to bortezomib. Given that plerixafor itself did not prove to be cytotoxic, we proposed that its therapeutic effect arises from inhibiting MM cell attachment to protective BM niches. Characterization of the CXCL12/CXCR4-axis revealed that neither bortezomib nor pomalidomide had an effect on CXCR4. Similarly, plerixafor had no effect on CXCR4, only slightly reduced CD49d and CD44 expression, but diminished CXCL12-induced pERK, pCXCR4 and actin polymerization in response to CXCL12 stimulation. Both flow and image cytometry allowed us to visualize this CXCL12-induced CXCR4 internalization, which was abrogated by Carfilzomib overcomes stroma protection due to pCXCR4 inhibition (A). Carfilzomib (Cfz; 20, 50, 100 nmol/l) was tested with three different treatment regimens in U266 and L363 cells. (a) Cells were treated in monoculture with a 1-h carfilzomib pulse and were allowed to recover for 24 h in fresh medium (U266 n = 9, L363 n = 6). (b) Multiple myeloma cell lines (MMCL) were treated in mono-culture continuously for 3 days with carfilzomib (n = 3). (c) MMCL were treated in M2-10B4 co-culture continuously for 3 days with carfilzomib (U266 n = 6, L363 n = 4). (B) U266 cells were co-cultured with M2-10B4 and treated with carfilzomib (20, 50, 100 nmol/l) alone or in combination with NOX-A12 for 72 h (100 nmol/l, n = 7). Results shown in C-D were obtained in U266 mono-cultured cells treated with a carfilzomib 1-h pulse regimen according to A.a. (C) The surface expression of CXCR4 and CD138 was measured by flow cytometry and presented as isotype-based mean expression of live cells (CXCR4 n = 11, CD138 n = 7). (D) CXCR4 total protein expression (clone 4G10), at serine 339 phosphorylated CXCR4 and b-actin expression were assessed by Western blot (representative example), pCXCR4/CXCR4 ratio (n = 4), CXCR4/b-actin ratio (n = 2). (E) Total protein levels of ERK-kinase, phosphorylated ERK (pERK) and b-actin expression were assessed by Western blot, pERK/ERK ratio (n = 4). (F) U266 monocultured cells were treated with a carfilzomib pulse (t = 1 h), were allowed to recover for 20 h, then starved for 4 h and stimulated with CXCL12 -15 min (n = 4). Western blot analysis was performed (pCXCR4/GAPDH ratios are shown). PI, proteasome inhibitor. plerixafor. These results supplement previous plerixafor-bortezomib in vitro and in vivo data (Alsayed et al, 2007; Azab et al, 2009; Roccaro et al, 2014 Roccaro et al, , 2015 and a phase I/II trial, which investigated plerixafor combined with VD in RRMM patients (Ghobrial et al, 2013) .
Given that CXCL12 binds not only to CXCR4 but also to CXCR7, the second CXCL12 chemokine receptor, we comprehensively analysed MM cells also for their surface expression of CXCR7. CXCR7 has been detected in different tissues (Tarnowski et al, 2010; S anchez-Mart ın et al, 2013; Puchert & Engele, 2014) : it regulates CXCL12 scavenging in splenic B-cells and co-activates transendothelial migration (Mazzinghi et al, 2008; Wang et al, 2012) , although previous data did not observe relevant CXCR7 surface expression on MM cells, possibly due to a lack of specificity of the previously used 72100-ab as compared to the 11G8-ab used in the present study (Berahovich et al, 2010; Azab et al, 2014) . The spectrum of available CXCR7 abs comprises four monoclonal and seven polyclonal abs. The majority has been abandoned due to significant weaknesses (Berahovich et al, 2010) : one ab-clone failed to stain MMCL endogenously expressing CXCR7 (358426; R&D System). A second and third ab stained tissue sections from CXCR7 knockout mice (12870 and 38089; Abcam, Cambridge, UK). Similarly, the 72100-ab, which had been utilized previously in MM (Azab et al, 2014) , has been reported to detect CXCR7 bands in the Jurkat T-cell line, which does not express CXCR7, illustrating its lack of specificity. In line with Berahovich et al (2010) , we therefore employed the 11G8-ab, which has high specificity for CXCR7 and is used for flow cytometry and immunohistochemistry (Burns et al, 2006; Miao et al, 2007) . We found CXCR7 to be highly expressed on malignant PCs. While we found that CXCR4 on MM cells was reduced by carfilzomib, CXCR7 remained unchanged, which indicates an independent role for CXCR7 in MM trafficking (e.g. inhibition of angiogenic mononuclear cells and tumour neovascularization; Azab et al, 2014) . This independent role of CXCR7 warranted the subsequent evaluation of CXCL12-based therapies, which could inhibit both CXCR4-and CXCR7-mediated CAM-DR. The L-stereo-isomer RNA aptamer NOX-A12 is a clinically available CXCL12 inhibitor, which blocks both CXCR4 and CXCR7 . We therefore assessed whether NOX-A12 may induce increased cytotoxicity when combined with the novel proteasome inhibitor carfilzomib (Arastu-Kapur et al, 2011; Lawasut et al, 2012) . Carfilzomib led to substantial MM cell cytotoxicity, both as a 1-h pulse or continuous 3-day treatment. This effect was decreased in stroma co-cultures, but could not be significantly restored by plerixafor or NOX-A12. We therefore hypothesized that carfilzomib itself modulates the attachment of MM cells by interfering with CXCL12/CXCR4-mediated CAM-DR (Bhutani et al, 2014) . Our analyses indeed showed that carfilzomib, different to bortezomib, downregulates surface CXCR4 and CD138 (Azab et al, 2009) . In line with the results of a phase II clinical trial, where carfilzomib reduced surface CXCR4 in a subset of patients (Bhutani et al, 2014) , carfilzomib reduced CXCR4 in U266 cells. Prior findings have shown that CXCR4 requires phosphorylation at S339 as an essential step for its recirculation to the cell surface and its function as a CXCL12 receptor (Shay et al, 2005; Tian et al, 2012) . In line with this, our data demonstrated that carfilzomib decreased CXCR4 phosphorylation at S339 both with and without CXCL12 stimulation, but did not alter total CXCR4, ERK and pERK. This suggests that carfilzomib does not entirely inhibit phosphorylation or protein synthesis, but acts as specific inhibitor of CXCR4 phosphorylation. To verify the clinical rationale and feasibility of our data, we included the results of two representative patients who received NOX-VD treatment at our centre (Ludwig et al, , 2017 . Both of the highly pre-treated and bortezomib-refractory patients showed impressive LC-reduction. Neither of these nor other patients in the entire trial showed lymphocyte dysfunction or extramedullary MM dissemination. NOX-VD resulted in similar responses in patients with and without previous exposure to bortezomib (Ludwig et al, , 2017 , suggesting that retreatment of bortezomib-sensitive subclones was not the main mechanism inducing response.
In conclusion, our data suggest that CXCR4, CXCL12 and CXCR7 act as valid targets to antagonize CAM-DR in MM, but also that the exact mechanisms of combination partners remain to be deciphered such as differences of bortezomib and carfilzomib. Further studies will need to define how adhesion interference of MM cells to BMSCs, through CXCR4-, CXCL12-and/or CXCR7-receptor signalling could best modify MM growth suppression. Moreover, revised administration of plerixafor and NOX-A12 seems warranted and forthcoming studies on the role of CXCR4, CXCL12 and CXCR7 inhibitors may improve the efficacy of this therapeutic approach for patients with MM.
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